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ABSTRACT 
 
Commiphora species (from which myrrh is obtained) has been a source of several novel and 
bio-active natural compounds. Traditionally, Commiphora (Burseraceae) is used in southern 
Africa for the treatment of ulcers, fevers, and as a remedy for snake and scorpion bites. In 
western Africa, the macerated stem is used in the treatment of rheumatic conditions. The resin 
of some Commiphora species is applied topically to aid in wound healing. Documented uses 
include antibacterial and antifungal properties, as well as cytotoxic, cytostatic and anti-oxidant 
activity. The botanical diversity of this genus in South Africa warrants a study of this plant 
group, to provide scientific evidence for the traditional use of Commiphora species in African 
healing rites. 
 
Ten Commiphora species were investigated. Fresh plant material of the selected species were 
identified and collected from natural populations in the Limpopo Province. Active 
compounds, viz. kaempferol and dihydrokaempferol, in C. glandulosa (stem) were isolated 
using bioassay-guided fractionation and identified using nuclear magnetic resonance 
spectroscopy. The stem and leaf extracts of each species were analysed for in vitro anti-
oxidant, antimicrobial, anti-inflammatory, anticancer activity, as well as cytotoxicity. The 
anti-oxidant activity of the extracts was investigated using the 2,2-diphenyl-1-picrylhydrazyl 
(DPPH) radical scavenging assay and the 2,2’-azino-bis(3-ethyl-benzthiazoline-6-sulfonic 
acid) (ABTS) assays. Extracts generally exhibited poor anti-oxidant activity in the DPPH 
assay, with the exception of C. schimperi (stem), C. neglecta (stem), C. tenuipetiolata (stem 
and leaf), and C. edulis (stem), which possessed IC50 values ranging between 7.31 μg/ml and 
10.81 μg/ml. Isolated compounds were subjected to the DPPH assay to determine the anti-
oxidant potential of each compound, separately and in combination to establish possible 
synergistic, antagonistic or additive effects. The flavonol, kaempferol (IC50 = 3.32 μg/ml) 
showed exceptional radical scavenging activity, in contrast to the low activity displayed by 
dihydrokaempferol (IC50 = 301.57 μg/ml), their combination being antagonistic. Greater anti-
oxidant activity was observed for most species in the ABTS assay when compared to the 
results obtained in the DPPH assay. The best activity was observed for the stem extracts of C. 
neglecta (IC50 = 7.28 μg/ml) and C. mollis (IC50 = 8.82 μg/ml).  
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ABSTRACT continued 
 
In vitro antimicrobial efficacy was determined against Gram-positive and Gram-negative 
bacteria as well as yeasts using the MIC microtiter plate assay. A greater selectivity was 
exhibited by the extracts against the Gram-positive bacteria and yeast than against the Gram-
negative bacteria. Using death kinetics studies (time-kill studies), the rate at which the 
antimicrobial agent kills pathogens over a 24-hour period was determined. The antibacterial 
activity of Commiphora marlothii (stem) was observed to begin at ca. 30 min of the exposure 
of S. aureus to the different concentrations of plant extract. All concentrations exhibited 
antibacterial activity, with a complete bactericidal effect achieved by all test concentrations by 
the 24th hour. Commiphora pyracanthoides (stem) displayed anti-inflammatory activity 
through good inhibition of the 5-LOX enzyme (IC50 = 27.86 μg/ml). 
 
The ability of extracts and kaempferol to inhibit the in vitro growth of three human cancer cell 
lines, namely the colon adenocarcinoma (HT-29), breast adenocarcinoma (MCF-7), and the 
neuronal glioblastoma (SF-268), was evaluated using the sulforhodamine (SRB) 
antiproliferative assay. The most active Commiphora species against the HT-29 cells were C. 
glandulosa (leaf and stem) and C. marlothii (leaf). The MCF-7 cell line was the most sensitive 
to indigenous Commiphora species, with C. edulis (leaf and stem), C. glandulosa (leaf and 
stem), C. marlothii (leaf), C. pyracanthoides (leaf and stem), C. schimperi (stem), and C. 
viminea (stem) all possessing an inhibition greater than 80% at 100 μg/ml. Commiphora 
glandulosa (leaf and stem) and C. pyracanthoides (leaf and stem) were the two most active 
species against the SF-268 cells, with IC50 values ranging between 68.50 μg/ml and 71.45 
μg/ml. The inhibition of the cancer cell proliferation by kaempferol in all three-cancer cell 
lines was determined, with IC50 values of 9.78 μg/ml in HT-29 cells, 20.21 μg/ml in MCF-7 
cells and 43.83 μg/ml in SF-268 cells. The microculture tetrazolium cellular viability (MTT) 
assay was used to determine the cellular toxicity of the extracts against transformed human 
kidney epithelium (Graham) cells. Commiphora glandulosa (stem) proved to be most toxic 
(IC50 = 30.5 μg/ml). The IC50 values for all other extracts were in excess of 95 μg/ml 
suggesting low in vitro toxicity for the majority of the species.  
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ABSTRACT continued 
 
A phytochemical investigation of the non-volatile constituents of the leaf and stems was 
conducted using high performance liquid chromatography (HPLC). The HPLC profiles and 
UV spectra of the stem extracts, and the representative flavonoid patterns in the leaf extracts 
of the species indicate that a similarity exists in their chemical fingerprint.  
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